These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19756835)

  • 1. Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission.
    Miyamura T; Sonomoto K; Nakamura M; Horai Y; Takahama S; Ando H; Minami R; Yamamoto M; Suematsu E
    Clin Rheumatol; 2010 Jan; 29(1):87-90. PubMed ID: 19756835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis.
    Laas K; Peltomaa R; Kautiainen H; Leirisalo-Repo M
    Clin Rheumatol; 2008 Jul; 27(7):927-32. PubMed ID: 18414967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.
    Iannone F; Gremese E; Gallo G; Sarzi-Puttini P; Botsios C; Trotta F; Gasperini S; Galeazzi M; Adami S; Cantini F; Sebastiani M; Gorla R; Marchesoni A; Giardina A; Foti R; Mele A; Bruschi E; Bagnato G; Erre GL; Lapadula G;
    Clin Rheumatol; 2014 Jan; 33(1):31-7. PubMed ID: 23954923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
    Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
    Genovese MC; Bathon JM; Fleischmann RM; Moreland LW; Martin RW; Whitmore JB; Tsuji WH; Leff JA
    J Rheumatol; 2005 Jul; 32(7):1232-42. PubMed ID: 15996057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
    van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
    BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
    Emery P; Breedveld F; van der Heijde D; Ferraccioli G; Dougados M; Robertson D; Pedersen R; Koenig AS; Freundlich B;
    Arthritis Rheum; 2010 Mar; 62(3):674-82. PubMed ID: 20187135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis.
    Wada T; Son Y; Ozaki Y; Nomura S; Iida H
    Mod Rheumatol; 2012 Nov; 22(6):824-30. PubMed ID: 22302136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption.
    Laganà B; Picchianti Diamanti A; Ferlito C; Germano V; Migliore A; Cremona A; Argento G; David V; Salemi S; D'Amelio R
    Int J Immunopathol Pharmacol; 2009; 22(2):447-54. PubMed ID: 19505397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Case of successful pregnancy and childbirth in a rheumatoid arthritis patient treated with etanercept].
    Furukawa K; Maeshima E; Ichinose M
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(1):47-51. PubMed ID: 23445732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit.
    Abarca J; Malone DC; Armstrong EP; Grizzle AJ; Cohen MD
    J Manag Care Pharm; 2004; 10(6):538-42. PubMed ID: 15548126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse events in rheumatoid arthritis patient with etanercept therapy: the appearance of osteomalacia].
    D'Amore M; Minenna G; D'Amore S
    Recenti Prog Med; 2005 Nov; 96(11):552-5. PubMed ID: 16499162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
    Genovese MC; Bathon JM; Martin RW; Fleischmann RM; Tesser JR; Schiff MH; Keystone EC; Wasko MC; Moreland LW; Weaver AL; Markenson J; Cannon GW; Spencer-Green G; Finck BK
    Arthritis Rheum; 2002 Jun; 46(6):1443-50. PubMed ID: 12115173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.
    Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G;
    Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.
    Weinblatt ME; Bathon JM; Kremer JM; Fleischmann RM; Schiff MH; Martin RW; Baumgartner SW; Park GS; Mancini EL; Genovese MC
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):373-82. PubMed ID: 20957659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.